Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Return on Sales (2022 - 2025)

Stoke Therapeutics has reported Return on Sales over the past 4 years, most recently at 0.41% for Q4 2025.

  • For Q4 2025, Return on Sales fell 41.0% year-over-year to 0.41%; the TTM value through Dec 2025 reached 0.0%, up 2.0%, while the annual FY2025 figure was 0.0%, 2.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.41% at Stoke Therapeutics, down from 0.04% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q1 2025 and troughed at 0.41% in Q4 2025.
  • A 4-year average of 0.08% and a median of 0.07% in 2024 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: grew 9bps in 2024 and later plummeted -41bps in 2025.
  • Year by year, Return on Sales stood at 0.08% in 2022, then fell by -23bps to 0.1% in 2023, then skyrocketed by 95bps to 0.0% in 2024, then tumbled by -8631bps to 0.41% in 2025.
  • Business Quant data shows Return on Sales for STOK at 0.41% in Q4 2025, 0.04% in Q3 2025, and 0.02% in Q2 2025.